Moreover, sensitivity analyses were conducted to strengthen the study results: both when restricting the comparison at patients with metastatic disease at the time of sampling and when restricting the comparison at HER2 IHC 2+ vs. HER2-0 we obtained results that are consistent with the overall study cohort. The gene discussed is ERBB2; the disease is metastatic neoplasm.